Skip to main content
Evidence Snapshot

Cyclin-dependent kinase 9

CHEMBL3116 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:37:24Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3116
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Cyclin-dependent kinase 9 as ChEMBL target CHEMBL3116, mapped to UniProt P50750. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Cyclin-dependent kinase 9
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL3116
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P50750
Cyclin-dependent kinase 9
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Cyclin-dependent kinase 9 matters

As of 2026-09-13

Cyclin-dependent kinase 9 is reviewed as Cyclin-dependent kinase 9 (UniProt P50750); Cyclin-dependent kinase 9 shows late clinical disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block.; 4 linked drugs keep this evidence frame grounded.; the current evidence base includes 9 approved drugs, 2788 compounds, and 581 assays, with lead potency reaching pChEMBL 10.8.

Disease context
chronic lymphocytic leukemia

Cyclin-dependent kinase 9 shows late clinical disease relevance led by chronic lymphocytic leukemia. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include ALVOCIDIB, BMS-387032, DINACICLIB.

Start review with chronic lymphocytic leukemia because it currently carries late clinical support. Linked drugs include ALVOCIDIB, BMS-387032, DINACICLIB, ZOTIRACICLIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 4 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 9 approved drugs, 2788 compounds, and 581 assays for this target. The dominant activity type is IC50. CHEMBL3694406 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL3694406 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
9 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Cyclin-dependent kinase 9 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P50750, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why chronic lymphocytic leukemia is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

2788
Total Compounds
581
Total Assays
9
Approved Drugs
IC50: 2286.0, KI: 426.0, EC50: 33.0, KD: 386.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3694406
 10.8 IC50 —
No preferred name
CHEMBL3694400
 10.7 IC50 —
No preferred name
CHEMBL3694402
 10.7 IC50 —
No preferred name
CHEMBL3694407
 10.5 IC50 —
No preferred name
CHEMBL3694401
 10.4 IC50 —

Approved Drugs

Structure Compound First Approval
MOMELOTINIB
CHEMBL1078178
 2023
PACRITINIB
CHEMBL2035187
 2022
ABEMACICLIB
CHEMBL3301610
 2017
PALBOCICLIB
CHEMBL189963
 2015
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T15:37:24Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL3116